Sign up to save your podcasts
Or
Share How This Biotech Founder Studies Breast Milk To Design Unique Therapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How This Biotech Founder Studies Breast Milk To Design Unique Therapeutics
Most AI drug discovery companies fail in clinical trials. Maolac’s success rate? 10 out of 10.
In this episode of Machine Dreams, CEO Maya Ashkenazi Otmazgin explains how her company uses “protein intelligence” to reverse-engineer breast milk’s biological playbook, designing therapeutics that mimic what nature already perfected.
We discuss why biological data is scarce, how Maolac compresses drug timelines without cutting safety corners, and why women’s biology demands different solutions than men’s.
If you’re tired of AI drug discovery vaporware, this conversation is for you.
View all episodes
By Kolawole Samuel Adebayo & Leah SternMost AI drug discovery companies fail in clinical trials. Maolac’s success rate? 10 out of 10.
In this episode of Machine Dreams, CEO Maya Ashkenazi Otmazgin explains how her company uses “protein intelligence” to reverse-engineer breast milk’s biological playbook, designing therapeutics that mimic what nature already perfected.
We discuss why biological data is scarce, how Maolac compresses drug timelines without cutting safety corners, and why women’s biology demands different solutions than men’s.
If you’re tired of AI drug discovery vaporware, this conversation is for you.